The efficacy and safety of the melatonin agonist β-methyl-6- chloromelatonin in primary insomnia: A randomized, placebo-controlled, crossover clinical trial

Journal of Clinical Psychiatry

Volumn 66, Issue 3, 2005, Pages 384-390

  Zemlan, Frank P ^a   Jeffery Mulchahey, J ^a   Scharf, Martin B ^b   Mayleben, David W ^c   Rosenberg, Russell ^d   Lankford, Alan ^e  

^a Phase 2 Discovery Inc   (United States)

^b Tri State Sleep Disorders Center   (United States)

^c Comm Res Mgmt Associates Inc ^*  (United States)

^d Neurotrials Research Inc   (United States)

^e Sleep Disorders Center of Georgia   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 CHLOROMELATONIN; BETA METHYL 6 CHLOROMELATONIN; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AMBLYOPIA; ARTICLE; BINDING AFFINITY; BLOOD PRESSURE; BODY TEMPERATURE; CIRCADIAN RHYTHM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEADACHE; HEART RATE; HUMAN; HYPOTHERMIA; INSOMNIA; LATENT PERIOD; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PHARYNGITIS; POLYSOMNOGRAPHY; PRIORITY JOURNAL; PSYCHOMOTOR PERFORMANCE; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SIDE EFFECT; TREATMENT OUTCOME;

EID: 16444367184     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/jcp.v66n0316     Document Type: Article

References (25)

1. Reiter RJ. The melatonin rhythm: both a clock and a calendar. Experientia 1993;49:654-664
2. Utiger RD. Melatonin: the hormone of darkness. N Engl J Med 1992;327:1377-1379
3. Attenburrow MEJ, Cowen PJ, Sharpley AL. Low dose melatonin improves sleep in healthy middle-aged subjects. Psychopharmacology (Berl) 1996;126:179-181
4. James SP, Mendelson WB, Sack DA, et al. The effect of melatonin on normal sleep. Neuropsychopharmacology 1987;1:41-44
5. Zhdanova IV, Wurtman RJ, Morabito C, et al. Effects of low oral doses of melatonin, given 2-4 hours before habitual bedtime, on sleep in normal young humans. Sleep 1996;19:423-431
6. Waldhauser F, Saletu B, Trinchard-Lugan I. Sleep laboratory investigations on hypnotic properties of melatonin. Psychopharmacology (Berl) 1990;100:222-226
7. Krauchi K, Cajochen C, Mori D, et al. Early evening melatonin and S-20098 advance circadian phase and nocturnal regulation of core body temperature. Am J Physiol 1997;272:R1189-1196
8. Krauchi K, Cajochen C, Wirz-Justice A. A relationship between heat loss and sleepiness: effects of postural change and melatonin administration. J Appl Physiol 1997;83:134-139
9. Gilbert SS, van den Heuvel CJ, Dawson D. Daytime melatonin and temazepam in young adult humans: equivalent effects on sleep latency and body temperatures. J Physiol 1999;514:905-914
10. Flaugh ME, Bruns RF, Clarke DO, et al. Preliminary clinical studies on the melatonin agonist LY156735. Presented at the Gorden Research Conference on Pineal Cell Biology 2000; Aug 27-Sept 1, 2000; Oxford, UK
11. Mulchahey JJ, Goldwater DR, Zemlan FP. A single blind, placebo controlled, across groups dose escalation study of the safety, tolerability, pharmacokinetics and pharmacodynamics of the melatonin analog β-methyl-6-chloromelatonin. Life Sci 2004;75:1843-1856
12. Fry J, Scharf M, Mangano R, et al, and Zaleplon Clinical Study Group. Zaleplon improves sleep without producing rebound effects in outpatients with insomnia. Int Clin Psychopharmacol 2000;15:141-152
13. Scharf MB, Roth T, Vogel GW, et al. A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia. J Clin Psychiatry 1994;55:192-199
14. Terzano MG, Parrino L, Spaggiari MC, et al. CAP variables and arousals as sleep electroencephalogram markers for primary insomnia. Clin Neurophysiol 2003;114:1715-1723
15. Edinger JD, Glenn DM, Bastian LA, et al. Daytime testing after laboratory or home-based polysomnography: comparisons of middle-aged insomnia sufferers and normal sleepers. J Sleep Res 2003;12:43-52
16. Dement WC. Objective measurements of daytime sleepiness and performance comparing quazepam with flurazepam in two adult populations using the Multiple Sleep Latency Test. J Clin Psychiatry 1991;52 (9, suppl):31-37
17. Saletu B, Anderer P, Brandstatter N, et al. Insomnia in generalized anxiety disorder: polysomnographic, psychometric, and clinical investigations before, during and after therapy with a long- versus a short-half-life benzodiazepine (quazepam versus triazolam). Neuropsychobiology 1994;29:69-90
18. Holbrook AM, Crowther R, Lotter A, et al. Meta-analysis of benzodiazepine use in the treatment of insomnia. Can Med Assoc J 2000;162:225-233
19. MacFarlane JG, Cleghorn JM, Brown GM, et al. The effects of exogenous melatonin on the total sleep time and daytime alertness of chronic insomniacs: a preliminary study. Biol Psychiatry 1991;30:371-376
20. Garfinkel D, Laudon M, Nof D, et al. Improvement of sleep quality in elderly people by controlled-release melatonin. Lancet 1995;346:541-544
21. Hughes RJ, Sack RL, Lewy AJ. The role of melatonin and circadian phase in age-related sleep-maintenance insomnia: assessment in a clinical trial of melatonin replacement. Sleep 1998;21:52-68
22. Montes LG, Uribe MP, Sotres JC, et al. Treatment of primary insomnia with melatonin: a double-blind, placebo-controlled, crossover study. J Psychiatry Neurosci 2003;28:191-196
23. Peterson L. Trends-in-Medicine. Association of Professional Sleep Societies (APSS); June 4-8, 2003; Chicago, Ill. Florida: Steven Snyder; 2003
24. Gilbert SS, van den Heuvel CJ, Kennaway DJ, et al. Peripheral heat loss: a predictor of the hypothermic response to melatonin administration in young and older women. Physiol Behav 1999;66:365-370
25. U.S. Food and Drug Administration. COSTART: Coding Symbols for a Thesaurus of Adverse Reaction Terms. 3rd Edition. Rockville, Md: U.S. Food and Drug Administration, Center for Drugs and Biologics, Division of Drug and Biological Products Experience; 1989